Loading…
miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer
Endometrial cancer is the most common gynecologic malignancy, whose incidence rate is on the rise. However, the underlying mechanisms of endometrial cancer are not very clear yet. miRNAs have been considered to be playing important roles in malignant behavior. Here, miR-652 was significantly upregul...
Saved in:
Published in: | Molecular cancer research 2018-12, Vol.16 (12), p.1927-1939 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Endometrial cancer is the most common gynecologic malignancy, whose incidence rate is on the rise. However, the underlying mechanisms of endometrial cancer are not very clear yet. miRNAs have been considered to be playing important roles in malignant behavior. Here, miR-652 was significantly upregulated in endometrial cancer, which correlated with shorter overall survival and earlier recurrence. Moreover, overexpression of miR-652 in endometrial cancer cells promoted proliferation, migration, and invasion
and facilitated tumor growth and metastasis
. In contrast, downregulation of miR-652 in endometrial cancer cells inhibited these processes both
and
. Mechanistically, miR-652 promotes proliferation and metastasis through directly targeting
. Both mRNA and protein level of RORA were negatively related with miR-652 and overexpression of RORA can rescue the promotion effect of miR-652. Further experiments indicated miR-652 overexpression can activate the Wnt/β-catenin pathway and RORA can downregulate β-catenin and function as a tumor suppressor in endometrial cancer. Collectively, these findings demonstrate that miR-652 functions as an oncomir in endometrial cancer. IMPLICATIONS: This study suggests that the miR-652 is a critical regulator of proliferation and metastasis in endometrial cancer and may serve as a therapeutic target. |
---|---|
ISSN: | 1541-7786 1557-3125 |
DOI: | 10.1158/1541-7786.MCR-18-0267 |